To evaluate the clinical efficacy and safety of short-term intensive statin therapy in patients with acute coronary syndrome (ACS).

A total of 218 ACS patients admitted in Hangzhou First People's Hospital from March 2013 to July 2013 were enrolled into this study. The patients were randomly assigned to receive atorvastatin 80 mg/d during hospitalization, and 40 mg/night after discharge for one month (intensive group, n=107); or receive atorvastin 20 mg during hospitalization and 20 mg/night after discharge for one month (control group, n=111). The biochemical indexes were measured on the admission and after one-month treatment.

After one-month treatment, the total cholesterol, triglycerides and LDL cholesterol of intensive group were significantly lower, and the high density lipoprotein cholesterol was higher than baseline values (0.75±0.14)mmol/L vs. (1.52±0.88)mmol/L, P<0.05; (2.21±0.78)mmol/L vs.(4.55±1.12)mmol/L, P<0.05; (1.76±0.31)mmol/L vs.(2.23±0.77) mmol/L, P<0.05; (1.15±0.34) vs.(1.52±0.41)mmol/L, P<0.05. The liver enzymes creatine kinase in intensive group was not significantly changed, but the creatinine levels decreased (82.53±23.85)μmol/L vs.(57.81±15.27) μmol/L, P<0.05, and the blood homocysteine and ultra-sensitivity C-reactive protein levels also decreased compared with the baseline (10.52±4.66)mmol/L vs.(30.70±18.82) mmol/L, P<0.05; (8.06±2.68)mg/L vs.(19.75±11.91)mg/L, P<0.05.

Short-term intensive statin therapy can effectively reduce blood lipid, cholesterol and homocysteine levels and raise HDL cholesterol levels; also with its anti-inflammatory and renal protective effect the therapy can provide more clinical benefit for patients with ACS.

Coronary Disease; Antilipemic agents; Treatment outcome